{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:20:13Z","timestamp":1788520813569,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1186\/s12920-019-0484-9","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T08:07:28Z","timestamp":1552550848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"12","author":[{"given":"Elena N.","family":"Voropaeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana I.","family":"Pospelova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail I.","family":"Voevoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir N.","family":"Maksimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriy L.","family":"Orlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga B.","family":"Seregina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"key":"484_CR1","volume-title":"WHO classification of tumors of Haematopoetic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stain H., et al. WHO classification of tumors of Haematopoetic and lymphoid tissues. Lyon; 2008."},{"issue":"11","key":"484_CR2","first-page":"23","volume":"98","author":"R Niroula","year":"2015","unstructured":"Niroula R, Butera J. Genetics and diffuse large B-cell lymphoma. R I Med J. 2015;98(11):23\u20136.","journal-title":"R I Med J"},{"issue":"7","key":"484_CR3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3324\/haematol.11011","volume":"92","author":"CF Skibola","year":"2007","unstructured":"Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica. 2007;92(7):960\u20139.","journal-title":"Haematologica."},{"issue":"16","key":"484_CR4","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","volume":"119","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119(16):3668\u201383. \n                    https:\/\/doi.org\/10.1182\/blood-2011-11-366062\n                    \n                  .","journal-title":"Blood."},{"issue":"2","key":"484_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/path.2637","volume":"220","author":"M Hollstein","year":"2010","unstructured":"Hollstein M, Hainaut P. Massively regulated genes: the example of TP53. J Pathol. 2010;220(2):164\u201317. \n                    https:\/\/doi.org\/10.1002\/path.2637\n                    \n                  .","journal-title":"J Pathol"},{"issue":"3","key":"484_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2141.2009.07739.x","volume":"146","author":"KJ Cheung","year":"2009","unstructured":"Cheung KJ, Horsman DE, Gascoyne RD. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol. 2009;146(3):257\u201369. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07739.x\n                    \n                  .","journal-title":"Br J Haematol"},{"issue":"2","key":"484_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc992","volume":"3","author":"AV Gudkov","year":"2003","unstructured":"Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3(2):117\u201329.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"484_CR8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/humu.10190","volume":"21","author":"S Peller","year":"2003","unstructured":"Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat. 2003;21(3):277\u201384.","journal-title":"Hum Mutat"},{"key":"484_CR9","unstructured":"Kopnin B.P., Kopnin P.B., Khromova N.V., Agapova L.S. Multifaced p53: variety of forms, functions, tumor-supressive and oncogenic activities. Clinical Oncohematology. Basic Research and Clinical Practice. Russian Journal (Klinicheskaya onkogematologiya). 2008; 1(1): 2--9. (in Engl.)"},{"key":"484_CR10","unstructured":"http:\/\/p53.iarc.fr\/download\/tp53_directsequencing_iarc.pdf\n                    \n                   (access date 31\/01\/2019)."},{"issue":"24","key":"484_CR11","doi-asserted-by":"crossref","first-page":"9551","DOI":"10.1073\/pnas.1200019109","volume":"109","author":"K Edlund","year":"2012","unstructured":"Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, et al. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A. 2012;109(24):9551\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"484_CR12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","volume":"28","author":"A Petitjean","year":"2007","unstructured":"Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622\u20139.","journal-title":"Hum Mutat"},{"key":"484_CR13","doi-asserted-by":"publisher","unstructured":"Adzhubei I., Jordan D.M., Sunyaev S.R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013; Ch.7: Unit 7.20. doi: \n                    https:\/\/doi.org\/10.1002\/0471142905.hg0720s76\n                    \n                  .","DOI":"10.1002\/0471142905.hg0720s76"},{"issue":"1","key":"484_CR14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0022-2836(91)90380-O","volume":"220","author":"S Brunak","year":"1991","unstructured":"Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol. 1991;220(1):49\u201365.","journal-title":"J Mol Biol"},{"issue":"1","key":"484_CR15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4238\/vol8-1gmr518","volume":"8","author":"LO Almeida","year":"2009","unstructured":"Almeida LO, Cust\u00f3dio AC, Pinto GR, Santos MJ, Almeida JR, Clara CA, et al. Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. Genet Mol Res. 2009;8(1):8\u201318.","journal-title":"Genet Mol Res"},{"issue":"11","key":"484_CR16","first-page":"3684","volume":"82","author":"SK Grebe","year":"1997","unstructured":"Grebe SK, McIver B, Hay ID, Wu PS, Maciel LM, Drabkin HA, et al. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab. 1997;82(11):3684\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Database issue","key":"484_CR17","doi-asserted-by":"publisher","first-page":"D962","DOI":"10.1093\/nar\/gks1033","volume":"41","author":"B Leroy","year":"2013","unstructured":"Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T. The TP53 website: an integrative resource Centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013;41(Database issue):D962\u20139. \n                    https:\/\/doi.org\/10.1093\/nar\/gks1033\n                    \n                  .","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"484_CR18","first-page":"1062","volume":"60","author":"TA Lehman","year":"2000","unstructured":"Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res. 2000;60(4):1062\u20139.","journal-title":"Cancer Res"},{"key":"484_CR19","doi-asserted-by":"crossref","unstructured":"Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E, Mazur SJ, Appella E, Vojtesek B, Blasco MA, Lane DP, Harris CC. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest. 2013;123(12):5247\u201357.","DOI":"10.1172\/JCI70355"},{"issue":"1","key":"484_CR20","first-page":"100","volume":"20","author":"JT Lu","year":"2012","unstructured":"Lu JT, Cen L, Zhou M. Prognostic value of P53 aberrations in diffuse large B-cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(1):100\u20132.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"5","key":"484_CR21","first-page":"576","volume":"29","author":"GX Sun","year":"2012","unstructured":"Sun GX, Cao XS, Li Q, Wang ZL. Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes andprognosis of diffuse large B-cell lymphoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2012;29(5):576\u201381.","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"issue":"5","key":"484_CR22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3760\/cma.j.issn.1003-9406.2014.01.020","volume":"31","author":"P Gao","year":"2014","unstructured":"Gao P, Li Q, Wang Z, Yan F, Lu C, Cao X. Significance of BCL-6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014;31(5):628\u201331. \n                    https:\/\/doi.org\/10.3760\/cma.j.issn.1003-9406.2014.01.020\n                    \n                  .","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi."},{"issue":"6","key":"484_CR23","first-page":"1413","volume":"39","author":"L Stefancikova","year":"2011","unstructured":"Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, et al. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Int J Oncol. 2011;39(6):1413\u201320.","journal-title":"Int J Oncol"},{"issue":"18","key":"484_CR24","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1038\/sj.onc.1210901","volume":"27","author":"H Stocklein","year":"2008","unstructured":"Stocklein H, Smardova J, Macak J, Katzenberger T, Holler S, Wessendorf S, et al. Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in difuse large B-cell lymphoma. Oncogene. 2008;27(18):2613\u201325.","journal-title":"Oncogene."},{"issue":"1","key":"484_CR25","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.12816\/0003336","volume":"14","author":"Y Tamimi","year":"2014","unstructured":"Tamimi Y, Al-Harthy S, Al-Haddabi I, Al-Kindi M, Babiker H, Al-Moundhri M, Burney I. The p53 mutation\/deletion profle in a small cohort of the Omani population with diffuse large B-cell lymphoma. Sultan Qaboos Univ Med J. 2014;14(1):e50\u20138.","journal-title":"Sultan Qaboos Univ Med J"},{"issue":"1","key":"484_CR26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/sj.leu.2403206","volume":"18","author":"I Simonitsch-Klupp","year":"2004","unstructured":"Simonitsch-Klupp I, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, et al. Diffuse large B-cell lymphomas with plasmablastic\/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia. 2004;18(1):146\u201355.","journal-title":"Leukemia."},{"issue":"19","key":"484_CR27","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL rituximab-CHOP consortium program study. Blood. 2012;120(19):3986\u201396.","journal-title":"Blood."},{"issue":"8","key":"484_CR28","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","volume":"112","author":"KH Young","year":"2008","unstructured":"Young KH, Leroy K, M\u00f8ller MB, Colleoni GW, S\u00e1nchez-Beato M, Kerbauy FR, Haioun C, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008;112(8):3088\u201398.","journal-title":"Blood."},{"issue":"24","key":"484_CR29","first-page":"6976","volume":"52","author":"T Frebourg","year":"1992","unstructured":"Frebourg T, Barbier N, Kassel J, Ng YS, Romero P, Friend SH. A functional screen for germ line p53 mutations based on transcriptional activation. \u0421ancer Res. 1992;52(24):6976\u20138.","journal-title":"\u0421ancer Res"},{"issue":"1","key":"484_CR30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/1055-9965.EPI-05-0444","volume":"15","author":"M Tennis","year":"2006","unstructured":"Tennis M, Krishnan S, Bonner M, Ambrosone CB, Vena JE, Moysich K, et al. p53 mutation analysis in breast tumors by a DNA microarray method. Cancer Epidemiol Biomark Prev. 2006;15(1):80\u20135.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"484_CR31","volume-title":"Eds. Moleculer biotechnology. Principles and applications of recombinant DNA. 2nd ed","author":"BR Glick","year":"1994","unstructured":"Glick BR, Pasternak JJ. Eds. Moleculer biotechnology. Principles and applications of recombinant DNA. 2nd ed. Washington: ASM Press; 1994."},{"issue":"4","key":"484_CR32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/mc.10159","volume":"38","author":"X Agirre","year":"2003","unstructured":"Agirre X, Novo FJ, Calasanz MJ, Larrayoz MJ, Lahortiga I, Valganon M, et al. TP53 is frequently altered by methylation, mutation, and\/or deletion in acute lymphoblastic leukaemia. Mol Carcinog. 2003;38(4):201\u20138.","journal-title":"Mol Carcinog"},{"issue":"2","key":"484_CR33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3835(01)00748-0","volume":"176","author":"IP Pogribny","year":"2002","unstructured":"Pogribny IP, James SJ. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Lett. 2002;176(2):169\u201374.","journal-title":"Cancer Lett"},{"issue":"4","key":"484_CR34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/labinvest.3780266","volume":"81","author":"JH Kang","year":"2001","unstructured":"Kang JH, Kim SJ, Noh DY, Park IA, Choe KJ, Yoo OJ, Kang HS. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Investig. 2001;81(4):573\u20139.","journal-title":"Lab Investig"},{"issue":"7","key":"484_CR35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/sj.onc.1206236","volume":"22","author":"M Garcia-Delgado","year":"2003","unstructured":"Garcia-Delgado M, Larrayoz MJ, Novo FJ. Methylation of CpG dinucleotides and\/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene. 2003;22(7):1070\u20132.","journal-title":"Oncogene."},{"issue":"12","key":"484_CR36","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/ijc.23038","volume":"121","author":"K Amara","year":"2007","unstructured":"Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Sriha B, et al. Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes. Int J Cancer. 2007;121(12):2693\u2013702.","journal-title":"Int J Cancer"},{"issue":"6","key":"484_CR37","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/0008-5472.CAN-04-2935","volume":"65","author":"Y Kakudo","year":"2005","unstructured":"Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res. 2005;65(6):2108\u201314.","journal-title":"Cancer Res"},{"issue":"34","key":"484_CR38","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1038\/sj.onc.1206511","volume":"22","author":"P Monti","year":"2003","unstructured":"Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, et al. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene. 2003;22(34):5252\u201360.","journal-title":"Oncogene."},{"issue":"2","key":"484_CR39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/carcin\/bgl132","volume":"28","author":"LR Dearth","year":"2007","unstructured":"Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, et al. Inactive full-leng th\u0435 p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis. 2007;28(2):289\u201398.","journal-title":"Carcinogenesis."},{"issue":"13","key":"484_CR40","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-05-0140","volume":"11","author":"AF Dekairelle","year":"2005","unstructured":"Dekairelle AF, Tombal B, Cosyns JP, Gala JL. \u0410ssessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Clin Cancer Res. 2005;11(13):4724\u201332.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"484_CR41","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","volume":"110","author":"KH Young","year":"2007","unstructured":"Young KH, Weisenburger DD, Dave BJ, Smith L, Sanger W, Iqbal J, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007;110(13):4396\u2013405.","journal-title":"Blood."},{"key":"484_CR42","unstructured":"Stefancikova L, Moulis M, Fabian P, Ravcukova B, Vasova I, Muzik J, Malcikova J, Falkova I, Slovackova J, Smardova J.\u00a0Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma.\u00a0Int J Oncol. 2010;36(3):699\u2013706."},{"issue":"29","key":"484_CR43","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"484_CR44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1074\/jbc.M310815200","volume":"279","author":"K Shiraishi","year":"2004","unstructured":"Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, et al. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem. 2004;279(1):348\u201355.","journal-title":"J Biol Chem"},{"issue":"11","key":"484_CR45","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.onc.1205250","volume":"21","author":"P Monti","year":"2002","unstructured":"Monti P, Campomenosi P, Ciribilli Y, Iannone R, Inga A, Abbondandolo A, et al. Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene. 2002;21(11):1641\u20138.","journal-title":"Oncogene."},{"issue":"27","key":"484_CR46","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/sj.onc.1204468","volume":"20","author":"P Campomenosi","year":"2001","unstructured":"Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, et al. \u042053 mutants can often transactivate promoters containin gap21 but not Bax or PIG3 responsive elements. Oncogene. 2001;20(27):3573\u20139.","journal-title":"Oncogene."},{"issue":"3","key":"484_CR47","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2018.06.003","volume":"174","author":"P Gao","year":"2018","unstructured":"Gao P, Xia JH, Sipeky C, Dong XM, Zhang Q, Yang Y, et al. Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus. Cell. 2018;174(3):576\u2013589.e18.","journal-title":"Cell"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-019-0484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12920-019-0484-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-019-0484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T20:15:50Z","timestamp":1583957750000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-019-0484-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":47,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1186\/s12920-019-0484-9","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"13 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Local Ethics Committee of Novosibirsk State Medical University. All participating patients signed an informed consent form before the study started.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"35"}}